Content area
Abstract
Objective
The cost-effectiveness of NUDT15 genetic testing-guided initial 6-mercaptopurine (6-MP) dosing in children with acute lymphoblastic leukemia (ALL) was evaluated.
Methods
A decision tree model was used to evaluate the cost to China’s medical system per quality-adjusted life-year (QALY) gained and cost per case of severe leukopenia avoided of NUDT15 genetic testing using public clinical data.
Results
Genetic testing-guided initial 6-MP dosing reduced overall costs by $518.61, and prevented 0.221 cases of Grade III–IV leukopenia and increased QALY by 0.00136 per patient. Results were robust in one-way analyses and probabilistic sensitivity analyses.
Conclusion
NUDT15 genetic testing prior to the initial administration of 6-MP in pediatric ALL patients in China is less expensive than standard dosing without genetic testing.
Details
; Zhuang Jing 2 ; Li, Na 3 ; Zheng, Bin 3 ; Sun, Hong 1 ; Cai JiaQin 1 ; Huang Xuhui 4 ; Zhang, Guifeng 5 ; Zhuang Jie 1 1 Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Department of Pharmacy, Fuzhou, People’s Republic of China (GRID:grid.415108.9) (ISNI:0000 0004 1757 9178)
2 Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Department of Plastic and Burn, Fuzhou, People’s Republic of China (GRID:grid.415108.9) (ISNI:0000 0004 1757 9178)
3 Fujian Medical University Union Hospital, Department of Pharmacy, Fuzhou, People’s Republic of China (GRID:grid.411176.4) (ISNI:0000 0004 1758 0478)
4 Fujian Provincial Hospital Jinshan Branch/Fujian Provincial Hospital South Branch, Department of Pharmacy, Fuzhou, People’s Republic of China (GRID:grid.415108.9) (ISNI:0000 0004 1757 9178)
5 Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Department of Oncology, Fuzhou, People’s Republic of China (GRID:grid.415108.9) (ISNI:0000 0004 1757 9178)